113 related articles for article (PubMed ID: 11859213)
21. Type II collagen, but not aggrecan expression, distinguishes clear cell chondrosarcoma and chondroblastoma.
Söder S; Oliveira AM; Inwards CY; Müller S; Aigner T
Pathology; 2006 Feb; 38(1):35-8. PubMed ID: 16484006
[TBL] [Abstract][Full Text] [Related]
22. Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression.
Hoang-Xuan K; He J; Huguet S; Mokhtari K; Marie Y; Kujas M; Leuraud P; Capelle L; Delattre JY; Poirier J; Broët P; Sanson M
Neurology; 2001 Oct; 57(7):1278-81. PubMed ID: 11591848
[TBL] [Abstract][Full Text] [Related]
23. Allelic loss of tumor suppressor genes in ameloblastic tumors.
Nodit L; Barnes L; Childers E; Finkelstein S; Swalsky P; Hunt J
Mod Pathol; 2004 Sep; 17(9):1062-7. PubMed ID: 15133474
[TBL] [Abstract][Full Text] [Related]
24. [Loss of heterozygosity on chromosome 9p13-23 in microdissected laryngeal squamous cell carcinoma by microsatellite analysis].
Xu X; An Q; Zhang J; Tang P; Cheng S
Zhonghua Er Bi Yan Hou Ke Za Zhi; 2001 Oct; 36(5):367-71. PubMed ID: 12761947
[TBL] [Abstract][Full Text] [Related]
25. Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas.
Ebert C; von Haken M; Meyer-Puttlitz B; Wiestler OD; Reifenberger G; Pietsch T; von Deimling A
Am J Pathol; 1999 Aug; 155(2):627-32. PubMed ID: 10433955
[TBL] [Abstract][Full Text] [Related]
26. p16MTS1/CDK4I mutations and concomitant loss of heterozygosity at 9p21-23 are frequent events in squamous cell carcinoma of the larynx.
Jares P; Fernández PL; Nadal A; Cazorla M; Hernández L; Pinyol M; Hernández S; Traserra J; Cardesa A; Campo E
Oncogene; 1997 Sep; 15(12):1445-53. PubMed ID: 9333020
[TBL] [Abstract][Full Text] [Related]
27. PTEN, DMBT1, and p16 alterations in diffusely infiltrating astrocytomas.
Fan X; Muñoz J; Sanko SG; Castresana JS
Int J Oncol; 2002 Sep; 21(3):667-74. PubMed ID: 12168116
[TBL] [Abstract][Full Text] [Related]
28. Allelic loss at 10q23.3 but lack of mutation of PTEN/MMAC1 in chromophobe renal cell carcinoma.
Sükösd F; Digon B; Fischer J; Pietsch T; Kovacs G
Cancer Genet Cytogenet; 2001 Jul; 128(2):161-3. PubMed ID: 11463457
[TBL] [Abstract][Full Text] [Related]
29. Allelic imbalances in endometrial stromal neoplasms: frequent genetic alterations in the nontumorous normal-appearing endometrial and myometrial tissues.
Moinfar F; Kremser ML; Man YG; Zatloukal K; Tavassoli FA; Denk H
Gynecol Oncol; 2004 Dec; 95(3):662-71. PubMed ID: 15581979
[TBL] [Abstract][Full Text] [Related]
30. Acquisition of the glioblastoma phenotype during astrocytoma progression is associated with loss of heterozygosity on 10q25-qter.
Fujisawa H; Kurrer M; Reis RM; Yonekawa Y; Kleihues P; Ohgaki H
Am J Pathol; 1999 Aug; 155(2):387-94. PubMed ID: 10433932
[TBL] [Abstract][Full Text] [Related]
31. Frequent loss of PTEN expression is linked to elevated phosphorylated Akt levels, but not associated with p27 and cyclin D1 expression, in primary epithelial ovarian carcinomas.
Kurose K; Zhou XP; Araki T; Cannistra SA; Maher ER; Eng C
Am J Pathol; 2001 Jun; 158(6):2097-106. PubMed ID: 11395387
[TBL] [Abstract][Full Text] [Related]
32. Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in cervical cancer.
Su TH; Chang JG; Perng LI; Chang CP; Wei HJ; Wang NM; Tsai CH
Gynecol Oncol; 2000 Feb; 76(2):193-9. PubMed ID: 10637069
[TBL] [Abstract][Full Text] [Related]
33. Loss of heterozygosity and tumor suppressor gene mutations in chondrosarcomas.
Yamaguchi T; Toguchida J; Wadayama B; Kanoe H; Nakayama T; Ishizaki K; Ikenaga M; Kotoura Y; Sasaki MS
Anticancer Res; 1996; 16(4A):2009-15. PubMed ID: 8712735
[TBL] [Abstract][Full Text] [Related]
34. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.
Suzuki H; Freije D; Nusskern DR; Okami K; Cairns P; Sidransky D; Isaacs WB; Bova GS
Cancer Res; 1998 Jan; 58(2):204-9. PubMed ID: 9443392
[TBL] [Abstract][Full Text] [Related]
35. PTEN/MMAC1 mutations and EGFR amplification in glioblastomas.
Liu W; James CD; Frederick L; Alderete BE; Jenkins RB
Cancer Res; 1997 Dec; 57(23):5254-7. PubMed ID: 9393744
[TBL] [Abstract][Full Text] [Related]
36. Loss of heterozygosity and mutational analysis of the PTEN/MMAC1 gene in synchronous endometrial and ovarian carcinomas.
Lin WM; Forgacs E; Warshal DP; Yeh IT; Martin JS; Ashfaq R; Muller CY
Clin Cancer Res; 1998 Nov; 4(11):2577-83. PubMed ID: 9829719
[TBL] [Abstract][Full Text] [Related]
37. Allelic imbalance and mutations of the PTEN gene in ovarian cancer.
Saito M; Okamoto A; Kohno T; Takakura S; Shinozaki H; Isonishi S; Yasuhara T; Yoshimura T; Ohtake Y; Ochiai K; Yokota J; Tanaka T
Int J Cancer; 2000 Jan; 85(2):160-5. PubMed ID: 10629071
[TBL] [Abstract][Full Text] [Related]
38. Somatic deletion mapping on chromosome 10 and sequence analysis of PTEN/MMAC1 point to the 10q25-26 region as the primary target in low-grade and high-grade gliomas.
Maier D; Zhang Z; Taylor E; Hamou MF; Gratzl O; Van Meir EG; Scott RJ; Merlo A
Oncogene; 1998 Jun; 16(25):3331-5. PubMed ID: 9681833
[TBL] [Abstract][Full Text] [Related]
39. Identification of PTEN/MMAC1 alterations in uncultured melanomas and melanoma cell lines.
Tsao H; Zhang X; Benoit E; Haluska FG
Oncogene; 1998 Jul; 16(26):3397-402. PubMed ID: 9692547
[TBL] [Abstract][Full Text] [Related]
40. Disparate expression of the PTEN gene: a novel finding in B-cell chronic lymphocytic leukaemia (B-CLL).
Leupin N; Cenni B; Novak U; Hügli B; Graber HU; Tobler A; Fey MF
Br J Haematol; 2003 Apr; 121(1):97-100. PubMed ID: 12670337
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
